このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Carna Biosciences マネジメント

マネジメント基準チェック /24

Carna Biosciences'の CEO はKohichiro Yoshinoで、 Apr2003年に任命され、の在任期間は 21.17年です。は、会社の株式の1.85%を直接所有しており、その価値は¥ 132.22M 。経営陣と取締役会の平均在任期間はそれぞれ12.3年と6.3年です。

主要情報

Kohichiro Yoshino

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	21.2yrs
CEOの所有権	1.8%
経営陣の平均在職期間	12.3yrs
取締役会の平均在任期間	6.3yrs

経営陣の近況

Recent updates

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Apr 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Apr 11

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Dec 26

CEO（最高経営責任者

Kohichiro Yoshino (75 yo)

21.2yrs

在職期間

Dr. Kohichiro Yoshino, Ph. D. is Independent Outside Director of Kringle Pharma, Inc since December 2018. Dr. Yoshino serves as the Chief Executive Officer of Carna Biosciences, Inc. He has been President...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kohichiro Yoshino	CEO, President & Representative Director	21.2yrs	データなし	1.85% ¥ 127.9m
Emi Yamamoto	GM of Business Mgt.	8.8yrs	データなし	0.30% ¥ 20.9m
Masaaki Sawa	GM of Research & Development Division	no data	データなし	0.59% ¥ 40.6m
Norio Aikawa	Head of Drug Discovery & Support Business	15.9yrs	データなし	0.57% ¥ 39.1m
Akinori Arimura	GM of Clinical Development	5.3yrs	データなし	0.091% ¥ 6.3m

12.3yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: 4572の経営陣は経験豊富で経験豊富です（平均在職期間は12.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Kohichiro Yoshino	CEO, President & Representative Director	21.2yrs	データなし	1.85% ¥ 127.9m
Emi Yamamoto	GM of Business Mgt.	8.3yrs	データなし	0.30% ¥ 20.9m
Masaaki Sawa	GM of Research & Development Division	9.3yrs	データなし	0.59% ¥ 40.6m
Norio Aikawa	Head of Drug Discovery & Support Business	20.3yrs	データなし	0.57% ¥ 39.1m
Akinori Arimura	GM of Clinical Development	1.3yrs	データなし	0.091% ¥ 6.3m
Tsuguo Ogasawara	Independent Outside Director	4.4yrs	データなし	0.028% ¥ 1.9m
Atsuo Arita	Independent Outside Director	4.4yrs	データなし	0.044% ¥ 3.1m
Teruo Takayanagi	Independent Outside Director	9.3yrs	データなし	0.0061% ¥ 421.0k
Takao Matsui	Independent Outside Director	4.4yrs	データなし	データなし
Kaoru Suzuki	Independent Outside Director	less than a year	データなし	データなし

6.3yrs

平均在職期間

75yo

平均年齢

経験豊富なボード: 4572の取締役会は経験豊富であると考えられます ( 6.3年の平均在任期間)。

Carna Biosciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

Recent updates

Carna Biosciences, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: JP¥23.21 loss per share (vs JP¥32.77 loss in 1Q 2023)

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Carna Biosciences, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: JP¥68.57 loss per share (vs JP¥99.07 loss in FY 2022)

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Third quarter 2023 earnings released: JP¥20.13 loss per share (vs JP¥31.91 loss in 3Q 2022)

Carna Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: JP¥21.43 loss per share (vs JP¥25.25 loss in 2Q 2022)

Carna Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: JP¥32.77 loss per share (vs JP¥1.12 loss in 1Q 2022)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc. to Report Q4, 2022 Results on Feb 10, 2023

Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Carna Biosciences, Inc. announced that it expects to receive ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Third quarter 2022 earnings released: JP¥31.91 loss per share (vs JP¥31.70 loss in 3Q 2021)

Carna Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: JP¥25.25 loss per share (vs JP¥39.45 loss in 2Q 2021)

Carna Biosciences, Inc. to Report Q2, 2022 Results on Aug 05, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Carna Biosciences, Inc. to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Consensus revenue estimates increase by 40%

Third quarter 2021 earnings released: JP¥31.70 loss per share (vs JP¥20.32 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥39.45 loss per share (vs JP¥17.31 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥23.06 loss per share (vs JP¥15.22 loss in 1Q 2020)

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

Revenue beats expectations, earnings disappoint

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

New 90-day high: JP¥1,433

Carna Biosciences, Inc. to Report Fiscal Year 2020 Results on Feb 12, 2021

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

New 90-day low: JP¥1,148

Third quarter 2020 earnings released: JP¥20.32 loss per share

New 90-day low: JP¥1,294

Carna Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low - JP¥1,371

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24